参芪降糖颗粒对2型糖尿病早期下肢动脉粥样硬化的影响

目的 观察参芪降糖颗粒对2型糖尿病(type2 diabetes mellitus,T2DM)早期下肢动脉粥样硬化性病变(lower extremity atherosclerotic disease,LEAD)患者动脉粥样硬化的影响.方法 将患者随机分为两组,治疗组30例口服参芪降糖颗粒,对照组30例口服西洛他唑,3个月为1个疗程,治疗前后分别检测患者下肢血管多普勒超声、白介素-6(1L-6)水平.结果 治疗组下肢动脉斑块厚度及动脉内中膜厚度较治疗前显著减少(t=3.376、3.468,P<0.05),血清IL-6水平较治疗前显著下降(t=3.345,P<0.05).结论 参芪降糖颗粒可减少斑块厚度、改善动脉内中膜增厚及稳定斑块,其作用机制町能足通过降低血清IL-6水平实现的.

Effect of Shenqi Jiangtang Keli on Atherosclerotic Changes of Lower Extremities in Patients with Early Type 2 Diabetes Mellitus

Objective To observe the effect of Shenqi Jiangtang Keli (SJK) on atherosclerotic disease (LEAD) of lower extremity in patients with early type 2 diabetes meliitus (T2DM). Methods The patients were randomly assigned to a control group and a treatment group. The 30 patients in the treatment group were treated by SJK and the 30 in the control group were given Cilostazo, with both groups were treated for 3 months. Lower extremity vascular color Doppler image, blood levels of interleukin-6 (IL-6) were measured before and after the treatment,. Results The thickness of atherosclerosis (AS) plaque and arterial intimamedia were obviously reduced (t=3.376, 3.468, P< 0.05 ), serum levels of IL-6 were also be lowered obviously (t=3.345, P<0.05) in the treatment group. While these indexes remained unchanged in the control group. Conclusion SJK has remarkable action in reducing the thickness of AS plaque and intima-media of artery. Its mechanism might be related with reducing serum IL-6 level.